- Home
- FIHL vs GPCR Comparison
FIHL vs GPCR Comparison
Compare FIHL & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIHL
- GPCR
- Stock Information
- Founded
- FIHL 2014
- GPCR 2016
- Country
- FIHL Bermuda
- GPCR United States
- Employees
- FIHL N/A
- GPCR N/A
- Industry
- FIHL
- GPCR
- Sector
- FIHL
- GPCR
- Exchange
- FIHL Nasdaq
- GPCR Nasdaq
- Market Cap
- FIHL 2.0B
- GPCR 1.8B
- IPO Year
- FIHL 2023
- GPCR 2023
- Fundamental
- Price
- FIHL $20.37
- GPCR $33.41
- Analyst Decision
- FIHL Buy
- GPCR Buy
- Analyst Count
- FIHL 9
- GPCR 5
- Target Price
- FIHL $20.72
- GPCR $86.80
- AVG Volume (30 Days)
- FIHL 451.1K
- GPCR 836.2K
- Earning Date
- FIHL 11-12-2024
- GPCR 11-13-2024
- Dividend Yield
- FIHL 1.96%
- GPCR N/A
- EPS Growth
- FIHL N/A
- GPCR N/A
- EPS
- FIHL 3.96
- GPCR N/A
- Revenue
- FIHL $2,299,900,000.00
- GPCR N/A
- Revenue This Year
- FIHL N/A
- GPCR N/A
- Revenue Next Year
- FIHL $13.79
- GPCR N/A
- P/E Ratio
- FIHL $5.15
- GPCR N/A
- Revenue Growth
- FIHL N/A
- GPCR N/A
- 52 Week Low
- FIHL $11.55
- GPCR $26.61
- 52 Week High
- FIHL $21.32
- GPCR $66.38
- Technical
- Relative Strength Index (RSI)
- FIHL 70.57
- GPCR 41.58
- Support Level
- FIHL $19.42
- GPCR $29.48
- Resistance Level
- FIHL $21.32
- GPCR $38.48
- Average True Range (ATR)
- FIHL 0.76
- GPCR 2.86
- MACD
- FIHL 0.21
- GPCR -0.59
- Stochastic Oscillator
- FIHL 77.70
- GPCR 30.90
About FIHL Fidelis Insurance Holdings Limited
Fidelis Insurance Holdings Ltd is a global (re)insurance company. It classify the business into three underwriting segments, namely Bespoke, Specialty and Reinsurance. Specialty primarily comprises property D&F, energy, marine and aviation lines. Bespoke primarily comprises credit and political risk and other tailored solutions for clients including transactional liabilities and credit insurance. Reinsurance primarily comprises property reinsurance.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.